Pfizer plans to invest $650 million over five years to build a new Manufacturing Technology Center at its research and development campus in Groton, Connecticut. The approximately 220,000-square-foot Groton Manufacturing Center will produce clinical active pharmaceutical ingredients and drug products for the company's clinical trials around the world.
Construction is expected to begin in the second quarter of 2027, with operations targeted to start in mid-2031. The project is intended to bring together employees and related operations currently spread across other buildings on the Groton campus, while modernizing infrastructure for the company's existing workforce.
Facility to Support Global Clinical Trials
The new center will focus on manufacturing materials and medicines used in clinical research. Clinical trial supplies are needed to evaluate potential treatments before they can be considered for wider use. Pfizer says the facility will strengthen its ability to support research and the development of new medicines for patients worldwide.
Raja Mangipudy, Pfizer's Groton site head, said the company's long history of scientific innovation in the city has helped generate discoveries that advance its research pipeline. He said the new center would build on that legacy and improve the company's ability to support clinical research and medicine development.
The project is described as a consolidation and modernization effort, bringing related work into a purpose-built facility designed around future clinical manufacturing requirements. The announcement does not specify how many new permanent jobs the center will create or detail any changes to the campus's overall employment level.
Long-Standing Pfizer Presence in Groton
Pfizer has maintained a presence in Groton since 1946 and established research and development operations there in 1959. The campus covers about 175 acres and contains more than two million square feet of laboratory and office space.
The site supports several functions, including scientific discovery, pharmaceutical sciences, clinical development and the global supply of materials for clinical research. It is one of Pfizer's major research and development locations.
Connecticut economic development officials welcomed the investment, describing it as a sign of confidence in the state's life sciences workforce and research capabilities. State economic development commissioner Daniel O'Keefe said the state's strategy focuses on innovation in sectors where its workforce, research institutions and established companies can compete.
The Connecticut business community also welcomed the project, saying it reflected the value of the state's life sciences sector. Industry representatives said major investments by global companies can signal that Connecticut is a place where businesses can invest, innovate and grow.
Construction Timeline
Planning and development work will precede construction, which Pfizer expects to start in the second quarter of 2027. The company is targeting mid-2031 for the facility to begin operations.
The investment will expand Pfizer's clinical manufacturing capabilities at a campus that has been central to its research activities for decades. The announced timeline remains a projection, and the center is not expected to begin operations for several years.
AN INDEPENDENT VOICE OF PUBLIC.







Join the conversation
Comments are reviewed before publication. Your email stays private.